Chemify develops Chemputation, an automated platform that combines the χDL universal chemical programming language, AI/ML for molecular design, ASSEMBLER route optimization software, and robotics to execute synthesis from digital code to physical molecules in closed-loop Design-Make-Test-Analyze cycles. The platform produces novel small molecules at gram scale using over 100 reaction classes and supports custom synthesis, derivatization libraries, and scale-up for preclinical testing. It serves pharma and biotech partners such as Dewpoint Therapeutics, Prepaire Labs, Sanacor, and Zeon Corporation for drug discovery targeting tuberculosis, malaria, opioids, cancer, neurodegeneration, and cardiometabolic diseases, as well as advanced materials. Founded in 2022 by Lee Cronin (CEO, PhD, from University of Glasgow research), leadership includes Knut Sauer (CTO, PhD), Kevin McGowan (CBO, PhD), Martin Stephenson (CFO), and Neil McCourt (COO). Chemify raised $43 million in Series A funding in August 2023 and more than $50 million in an oversubscribed Series B in October 2025 from investors including Wing Capital, Insight Partners, Triatomic Capital, 8VC, and BlueYard Capital. Headquarters are at Advanced Research Centre, 11 Chapel Lane, Glasgow G11 6EW, UK, with a Chemifarm facility at UNIT 8/9, OakBank Industrial Estate, Maryhill, Glasgow G20 7LU, UK.